CG Oncology Inc (CGON)

Currency in USD
40.05
-0.03(-0.07%)
Closed·
39.50-0.55(-1.37%)
·
CGON is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
39.7240.85
52 wk Range
14.8046.01
Key Statistics
Prev. Close
40.08
Open
39.94
Day's Range
39.72-40.85
52 wk Range
14.8-46.01
Volume
855.48K
Average Volume (3m)
907.86K
1-Year Change
42.37%
Book Value / Share
9.02
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CGON Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
70.71
Upside
+76.57%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period

CG Oncology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

CG Oncology Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

CG Oncology Inc SWOT Analysis


Creto's Promise
Explore CG Oncology's lead asset Creto, showing promising efficacy in non-muscle invasive bladder cancer treatment with extended response duration
Market Race
Delve into the competitive landscape as CG Oncology and Johnson & Johnson vie for dominance in the NMIBC market with innovative therapies
Financial Fortitude
Learn about CG Oncology's robust financial position, with $550 million in cash reserves supporting ongoing development and potential commercialization
Future Catalysts
Discover upcoming milestones, including crucial data presentations and regulatory submissions, that could significantly impact CG Oncology's market valuation
Read full SWOT analysis

Compare CGON to Peers and Sector

Metrics to compare
CGON
Peers
Sector
Relationship
P/E Ratio
−21.3x−2.4x−0.6x
PEG Ratio
1.06−0.100.00
Price/Book
4.7x1.3x2.6x
Price / LTM Sales
1,486.1x16.7x3.2x
Upside (Analyst Target)
64.7%135.9%41.8%
Fair Value Upside
Unlock17.8%5.1%Unlock

Analyst Ratings

15 Buy
0 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 70.71
(+76.57% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wedbush
Buy70.00+74.78%-New Coverage11/12/2025
Truist Securities
Buy62.00+54.81%-New Coverage24/11/2025
Morgan Stanley
Buy82.00+104.74%79.00Maintain17/11/2025
RBC Capital
Buy61.00+52.31%53.00Maintain17/11/2025
Guggenheim
Buy90.00+124.72%-New Coverage08/10/2025

Earnings

Latest Release
Nov 14, 2025
EPS / Forecast
-0.57 / --
Revenue / Forecast
1.67M / 20.00K
EPS Revisions
Last 90 days

People Also Watch

104.83
NUVL
-0.84%
8.88
KYTX
+9.23%
32.20
MBX
-7.47%
77.30
APGE
-0.90%

FAQ

What Is the CG Oncology (CGON) Share Price Today?

The live CG Oncology share price today is 40.05

What Stock Exchange Does CG Oncology (CGON) Trade On?

CG Oncology is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for CG Oncology?

The stock symbol (also called a 'ticker') for CG Oncology is "CGON."

What Is the Current CG Oncology Market Cap?

As of today, CG Oncology market capitalisation is 3.23B.

What Is CG Oncology's (CGON) Earnings Per Share (TTM)?

The CG Oncology EPS is currently -2.03 (Trailing Twelve Months).

When Is the Next CG Oncology Earnings Date?

CG Oncology's next earnings report will be released on 14 Nov 2025.

Is CGON a Buy or Sell From a Technical Analyst Perspective?

Based on today's CG Oncology moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has CG Oncology Stock Split?

CG Oncology has split 0 times. (See the CGON stock split history page for full effective split date and price information.)

How Many Employees Does CG Oncology Have?

CG Oncology has 113 employees.

What is the current trading status of CG Oncology (CGON)?

As of 24 Dec 2025, CG Oncology (CGON) is trading at a price of 40.05, with a previous close of 40.08. The stock has fluctuated within a day range of 39.72 to 40.85, while its 52-week range spans from 14.80 to 46.01.

What Is CG Oncology (CGON) Price Target According to Analysts?

The average 12-month price target for CG Oncology is USD70.71429, with a high estimate of USD100 and a low estimate of USD55. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +76.57% Upside potential.

What Is the CGON Premarket Price?

CGON's last pre-market stock price is 41.39. The pre-market share volume is 422.00, and the stock has decreased by 1.31, or 3.27%.

What Is the CGON After Hours Price?

CGON's last after hours stock price is 39.50, the stock has decreased by -0.55, or -1.37%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.